<DOC>
	<DOCNO>NCT01384630</DOCNO>
	<brief_summary>This 73-day phase II , open label trial true human monoclonal antibody RA-18C3 subject moderate severe plaque psoriasis . Ten ( 10 ) subject receive 200 mg RA-18C3 via subcutaneous injection . Subjects receive injection Days 0 , 21 , 42 total 3 injection . Study drug administer close observation facility equip handle medical emergency . Subjects discharge facility least 1 hour follow end injection 1 hour vital sign stabilize . Safety assess pre- post-treatment serial measurement vital sign , clinical laboratory assessment , record adverse clinical event .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Efficacy RA-18C3 Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subjects 18 year age old 2 . Diagnosis plaque psoriasis ≥ 6 month ; INCLUDING subject chronic guttate lesion . 3 . Psoriasis areaandseverity index ( PASI ) score ≥ 12 4 . Involvement ≥ 5 % bodysurface area 5 . For female subject childbearing age , negative urine pregnancy test screen specify time point throughout trial . For subject reproductive potential , willingness utilize adequate , double barrier contraception study include 3 month study completion . Sexually active men must use accepted method contraception study include 3 month study completion . 6 . Signed date Institutional Review Board ( IRB ) approve informed consent protocolspecific screening procedure perform 1 . Treatment biologicals investigational agent within last 4 week ( 5 halflives , whichever long ) . 2 . Treatment conventional systemic psoriasis therapy within last 4 week 3 . Treatment phototherapy within last 4 week 4 . Topical psoriasis treatment last 2 week 5 . History uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent stroke ( within 3 month ) , ongoing congestive heart failure , condition , opinion investigator , would put subject risk participation protocol . 6 . Hemoglobin &lt; 10.0 g/dL , WBC &lt; 3.0 x 103/mm3 , platelet count &lt; 125 x 103/mm3 , creatinine &gt; 1.5mg/dL , AST/ALT &gt; 2 x ULN , alkaline phosphatase &gt; 2 x ULN 7 . Known HIV antibody , hepatitis B surface antigen and/or hepatitis C antibody . 8 . History malignancy within 5 year prior study entry carcinoma situ cervix , adequately treat , nonmetastatic squamous basal cell carcinoma skin . 9 . History severe allergic anaphylactic reaction humanize murine monoclonal antibody . 10 . History tuberculosis ( latent active ) positive Interferongamma release assay ( IGRA ) 11 . Infectious disease : CRP &gt; 30 mg/L , fever , infection require treatment antibiotic within 3 week prior Screening 12 . Immunodeficiency 13 . History treatment Tysabri Raptiva 14 . Female subject pregnant , plan become pregnant course study , breastfeed 15 . Receipt live ( attenuate ) vaccine within 3 month prior Screening 16 . Major surgery within 28 day prior Day 0 17 . Participation investigational drug device trial within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>